Improving corneal treatment for keratoconus using advanced techniques
Advanced transepithelial corneal collagen crosslinking
['FUNDING_R21'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-10741684
This study is testing a new way to improve a treatment for keratoconus that helps strengthen the cornea without removing any surface cells, aiming to make the procedure safer and help you heal better.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-10741684 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing a procedure called transepithelial corneal collagen crosslinking (CXL) to treat keratoconus, a condition that weakens the cornea and affects vision. The innovative approach aims to deliver riboflavin, oxygen, and UV light more effectively without removing the corneal surface cells, which can lead to complications. By using advanced technology, the researchers hope to improve the effectiveness of the treatment and reduce the risks associated with the standard procedure. Patients may experience better healing and fewer side effects as a result of this new method.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with keratoconus who are experiencing progressive vision loss.
Not a fit: Patients with stable keratoconus who do not require intervention or those with other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with keratoconus, potentially preserving their vision and reducing the need for corneal transplants.
How similar studies have performed: Previous research has shown that corneal collagen crosslinking can effectively halt the progression of keratoconus, but this specific advanced transepithelial approach is novel and has not been extensively tested.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, DAVID — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: HUANG, DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.